| Literature DB >> 35872861 |
Mi Zhang1,2, Zili Zhou1,2, Jiahao Yun2, Rui Liu2, Jie Li2, Yimeng Chen2, HongXin Cai3, Heng Bo Jiang1,2, Eui-Seok Lee4, Jianmin Han1, Yunhan Sun2.
Abstract
This study is aimed at performing a systematic review and a network meta-analysis of the effects of several membranes on vertical bone regeneration and clinical complications in guided bone regeneration (GBR) or guided tissue regeneration (GTR). We compared the effects of the following membranes: high-density polytetrafluoroethylene (d-PTFE), expanded polytetrafluoroethylene (e-PTFE), crosslinked collagen membrane (CCM), noncrosslinked collagen membrane (CM), titanium mesh (TM), titanium mesh plus noncrosslinked (TM + CM), titanium mesh plus crosslinked (TM + CCM), titanium-reinforced d-PTFE, titanium-reinforced e-PTFE, polylactic acid (PLA), polyethylene glycol (PEG), and polylactic acid 910 (PLA910). Using the PICOS principles to help determine inclusion criteria, articles are collected using PubMed, Web of Science, and other databases. Assess the risk of deviation and the quality of evidence using the Cochrane Evaluation Manual, and GRADE. 27 articles were finally included. 19 articles were included in a network meta-analysis with vertical bone increment as an outcome measure. The network meta-analysis includes network diagrams, paired-comparison forest diagrams, funnel diagrams, surface under the cumulative ranking curve (SUCRA) diagrams, and sensitivity analysis diagrams. SUCRA indicated that titanium-reinforced d-PTFE exhibited the highest vertical bone increment effect. Meanwhile, we analyzed the complications of 19 studies and found that soft tissue injury and membrane exposure were the most common complications.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35872861 PMCID: PMC9303140 DOI: 10.1155/2022/7742687
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Inclusion and exclusion criteria.
| Inclusion criteria | Exclusion criteria | |
|---|---|---|
| Language | English | Else |
| Study design | Randomized controlled trials/case series | Nonrandomized controlled trials (no control group); studies reported only in the following forms: retrospective studies, review articles, and literature reviews; publications using replicated information |
| Intervention | Comparison of two or more membranes | Studies involving only one membrane: the membrane studied is not in the range of the selected 7 membranes |
| Type of operation | GBR/GTR | Else |
| Surgical site | In the human body; in the mouth | Else |
| Method | Include patient selection criteria and relevant information; include a description of the procedure | The patient was younger than 18 |
| Outcome | Includes results related to vertical bone gain; includes results related to complications | Excludes results related to vertical bone gain; complication-related results are not included |
Search strategies for PubMed.
| Search subject | Strategy | Result |
|---|---|---|
| #1 Intervention | “membranal”[All Fields] OR “membrane s”[All Fields] OR “membraneous”[All Fields] OR “membranes”[MeSH Terms] OR “membranes”[All Fields] OR “membrane”[All Fields] OR “membranous”[All Fields] | 1162158 |
| #2 Position of study | “dentistry”[MeSH Terms] OR “dentistry”[All Fields] OR “dentistry s”[All Fields] | 661109 |
| #3 Type of study | “GBR”[All Fields] OR (“guided tissue regeneration” [MeSH Terms] OR (“guided”[All Fields] AND “tissue”[All Fields] AND “regeneration”[All Fields]) OR “guided tissue regeneration”[All Fields] | 11476 |
| #4 Article type | “randomized controlled trial”[Publication Type] | 569132 |
| #5 Object of study | “humans”[MeSH Terms] | 20460648 |
| #6 Combination of all search keywords | #1 AND #2 AND #3 AND #4 AND #5 | 369 |
Figure 1Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flowchart of the search strategy for the systematic review.
Characteristics of the included studies.
| Study ID | Membrane | Patients ( | No. of patients (mean age; range of age) (in years) | Bone graft materials | Follow-up time (months) | Vertical bone gain (mm/%) | GBR/GTR |
|---|---|---|---|---|---|---|---|
| Ronda et al. [ | Titanium-reinforced, d-PTFE | 12/38 | 23 (49.60/30–78) | Autologous bone and mineralized bone allograft (1 : 1) | 6 | 5.49 ± 1.58 mm | GBR |
| Titanium-reinforced | 11/40 | 4.91 ± 1.78 mm | |||||
| Pruthi et al. [ | e-PTFE | 17/17 | 17 (56.50/35–75) | NA | 12 | 1.00 ± 2.03 mm | GTR |
| CM | 17/17 | 0.81 ± 1.80 mm | |||||
| Moses et al. [ | CM | 28/53 | 28 (50.50/NA) | Autogenous bone chips mixed with either bovine bone mineral | 6–8 | 75.11 ± 18.99% | GBR |
| e-PTFE | 17/34 | 17 (55.40/NA) | 75.26 ± 24.36% | ||||
| Annen et al. [ | CCM | 9/9 | 9 (50.20/NA) | Bovine bone mineral granules | 6 | 1.80 ± 1.60 mm | GBR |
| CM | 9/9 | 4.70 ± 3.30 mm | |||||
| Carpio et al. [ | CM | 23/23 | 48 (NA/NA) | Anorganic bovine bone plus; autogenous bone chips (1 : 1) | 6 | 2.65 ± 0.61 mm | GBR |
| e-PTFE | 25/25 | 2.26 ± 0.66 mm | |||||
| Lee et al. [ | CM | 14/14 | 28 (53.30/31–75) | Xenograft bone substitutes | 4 | 5.00 ± 2.50 mm | GBR |
| CCM | 14/14 | 2.90 ± 2.30 mm | |||||
| Scheyer et al. [ | CM | 19/19 | 40 (NA/18–70) | Demineralized allograft | 6 | 6.24 ± 2.98 mm | GBR |
| CCM | 21/21 | Deproteinized bovine bone mineral | 5.29 ± 3.73 mm | ||||
| Arbab et al. [ | CM | 12/12 | 12 (53.00/25–73) | Cancellous allograft and bovine-derived xenograft | 4 | 1.20 ± 1.50 mm | GBR |
| d-PTFE | 12/12 | 12 (52.00/30–73) | 0.50 ± 1.60 mm | ||||
| Naenni et al. [ | CM | 13/13 | 27 (51.85/NA) | Demineralized bovine bone mineral | 6 | 3.41 ± 2.33 mm | GBR |
| Titanium-reinforced; e-PTFE | 14/14 | 2.14 ± 2.06 mm | |||||
| Cucchi et al. [ | d-PTFE | 19/54 | 36 (52.00/NA) | Autogenous bone and bone allograft (1 : 1) | 12 | 4.20 ± 1.00 mm | GBR |
| TM + CCM | 17/44 | 4.10 ± 1.00 mm | |||||
| Lim et al. [ | CCM | 12/12 | 12 (53.83/NA) | Collagenated porcine bone | 4 | −1.50 ± 3.00 mm | GBR |
| CM | 14/14 | 14 (48.14/NA) | Collagenated bovine bone | 0.70 ± 1.80 mm | |||
| Maiorana et al. [ | Titanium-reinforced; d-PTFE | 5/5 | 5 (54.20/38–65) | Autogenous bone and deproteinized bovine bone mineral particles (1 : 1) | 8 | 4.20 ± 2.20 mm | GBR |
| TM | 5/5 | 1.50 ± 1.60 mm | |||||
| Teparat et al. [ | e-PTFE | 10/9 | 10 (NA/40–65) | NA | 9 | 3.30 ± 1.70 mm | GBR |
| PLA | 10/10 | 2.90 ± 1.20 mm | |||||
| Blumenthal [ | e-PTFE | 12/12 | 12 (NA/31–80) | NA | 12 | 1.00 ± 1.04 mm | GBR |
| CM | 12/12 | 1.58 ± 1.16 mm | |||||
| Christgau et al. [ | PLA 910 | NA/16 | 11 (40.40/23–59) | NA | 12 | 5.50 ± 1.50 mm | GTR |
| e-PTFE | NA/14 | 5.60 ± 2.20 mm | |||||
| Merli et al. [ | CM | 11/42 | 11 (44.60/29–59) | Autologous bone | 72 | 0.58 ± 0.66 mm | GBR |
| Titanium-reinforced; e-PTFE | 10/55 | 10 (49.90/36–69) | 0.49 ± 0.53 mm | ||||
| Kim et al. [ | PLA 910 | 8/8 | 8 (NA/NA) | NA | 6 | 3.00 ± 1.70 mm | GTR |
| e-PTFE | 8/8 | 2.60 ± 1.40 mm | |||||
| Karapataki et al. [ | PLA | 10/10 | 19 (43.00/NA) | NA | 12 | 4.40 ± 1.70 mm | GTR |
| e-PTFE | 9/9 | 3.00 ± 1.70 mm | |||||
| Choi et al. [ | TM | 15/17 | 100 (57.10/20–82) | An allograft bone | 6 | 3.20 ± 1.70 mm | GBR |
| TM + CCM | 56/72 | 3.10 ± 1.20 mm | |||||
| TM + CM | 29/40 | 3.00 ± 1.20 mm | |||||
| Friedmann et al. [ | CCM | 17/37 | 37 (NA/24–69) | A coagulum was formed by the calcium phosphate grafting material | 6 | / | GBR |
| CM | 20/36 | ||||||
| Tal et al. [ | CCM | 52/52 | 52 (46.00/20–70) | Deproteinized bovine bone mineral | 6 | GBR | |
| CM | 52/52 | ||||||
| Weltman et al. [ | PLA | 30/16 | 30 (NA/26–64) | NA | 12 | GBR | |
| e-PTFE | 30/14 | ||||||
| Atef et al. [ | CM | 20/10 | 20 (NA/20–60) | Autogenous and anorganic bovine bone mineral bone mixture (1 : 1) | 6 | GBR | |
| TM | 20/10 | ||||||
| Jung et al. [ | PEG | 57/57 | 117 (48.70/19–77) | A synthetic bone filler | 6 | GBR | |
| BG | 57/57 | ||||||
| Jung et al. [ | PEG | 19/19 | 19 (48.00/32–72) | A natural bone mineral of bovine origin | 6 | GBR | |
| CM | 18/18 | 18 (54.00/23–80) | |||||
| Cucchi et al. [ | TM | 15/34 | 30 (NA/NA) | Autogenous bone and bone xenograft (1 : 1) | 6 | GBR | |
| TM + CCM | 15/37 | ||||||
| Becker et al. [ | CCM | 23/41 | 23 (44.90/NA) | Natural bone mineral | 4 | GBR | |
| CM | 26/37 | 26 (42.40/NA) |
Figure 2A network geometry plot. The plot presents the result of a network meta-analysis of the direct comparison of the 11 interventions. The width of the lines is proportional to the number of direct lines comparing every pair of interventions, and the size of every blue dot is proportional to the sample size of the interventions.
Figure 3Funnel plot of publication bias. The horizontal axis represents the difference between the study-specific effect sizes from the corresponding comparison-specific summary effect. The vertical axis represents the standard error of the effect size. The red line represents the null hypothesis, in which the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates.
Figure 4A forest map of pairwise comparison. A forest plot of pairwise comparison. The black horizontal lines represent the confidence interval (CI) of each study. The black solid diamonds represent the standard mean difference (SMD) for each study. The blue hollow diamond represents the result of pairwise comparison or the result of the entire study. The gray squares represent the weight of individual studies; therefore, the larger the sample size, the larger the weight and the larger the square area. The black vertical line in the middle is an invalid line.
Figure 5Plots of the SUCRA for all treatments included in this study. The SUCRA for all interventions that were included. The plot shows the percentage and ranking of the effectiveness of each treatment.
Node-splitting analysis of inconsistency.
| Side | Direct | Indirect | Difference | ||||
|---|---|---|---|---|---|---|---|
| MD | SE | MD | SE | MD | SE |
| |
| d-PTFE vs CM | 0.4357833 | 0.5289967 | 1.163483 | 1.104742 | −0.7277 | 1.224864 | 0.552 |
| d-PTFE vs TM + CCM | −0.992163 | 0.3874848 | −0.8464555 | 1.17107 | 0.7472392 | 1.233511 | 0.545 |
| e-PTFE vs CM | 0.2239182 | 0.2175388 | 0.7504707 | 14.15419 | −0.5265525 | 14.15584 | 0.970 |
| e-PTFE vs PLA | 0.2455775 | 0.3966155 | −0.7071713 | 44.73296 | 0.9527488 | 44.73485 | 0.983 |
| e-PTFE vs PEG | 0.0640996 | 0.369438 | −0.6947047 | 44.73486 | 0.7588043 | 44.73644 | 0.986 |
| CCM vs CM | 0.2286887 | 0.2530728 | 1.142997 | 31.63677 | −0.9143078 | 31.63774 | 0.977 |
| CM vs titanium-reinforced e-PTFE | −0.3001702 | 0.3116784 | 0.4459553 | 1.193876 | −0.7461255 | 1.233879 | 0.545 |
| TM vs TM + CM | −0.155983 | 0.4390793 | 1.3408 | 2.415155 | −1.496783 | 2.468483 | 0.544 |
| TM vs TM + CCM | −0.0779806 | 0.4261512 | 0.6701218 | 1.158239 | −0.7481025 | 1.234139 | 0.544 |
| TM vs titanium-reinforced d-PTFE | 1.244603 | 0.8095491 | 0.4960574 | 0.9320917 | 0.7485455 | 1.234571 | 0.544 |
| TM + CM vs TM + CCM | 0.0779914 | 0.3843957 | 1.57247 | 2.441477 | −1.494478 | 2.467023 | 0.545 |
| Titanium-reinforced e-PTFE vs titanium-reinforced d-PTFE | −0.3406294 | 0.40123 | −1.088411 | 1.167402 | 0.7477821 | 1.234428 | 0.545 |
Figure 6Risk of bias graph.
Figure 7Risk of bias summary.
GRADE summary of randomized controlled clinical trials included in the final analysis.
| Comparison | Certainty | Downgrading due to |
|---|---|---|
| A vs D | ⨁⨁◯◯, low | Study limitation, imprecision |
| A vs G | ⨁⨁◯◯, low | Study limitation, imprecision |
| B vs D | ⨁⨁◯◯, low | Study limitation, imprecision |
| B vs J | ⨁⨁◯◯, low | Study limitation, imprecision |
| B vs K | ⨁⨁◯◯, low | Study limitation, imprecision |
| C vs D | ⨁◯◯◯, very low | Study limitation, inconsistency, imprecision |
| D vs I | ⨁⨁◯◯, low | Study limitation, imprecision |
| E vs F | ⨁⨁◯◯, low | Study limitation, imprecision |
| E vs G | ⨁⨁◯◯, low | Study limitation, imprecision |
| E vs H | ⨁⨁◯◯, low | Study limitation, imprecision |
| F vs G | ⨁⨁◯◯, low | Study limitation, imprecision |
| H vs I | ⨁⨁◯◯, low | Study limitation, imprecision |
| Ranking of treatments | ⨁⨁◯◯, low | Study limitation, imprecision |
Figure 8Influence of individual studies on overall results.
Figure 9Results of the complication analysis. (red: number of control group occurrences > number of experimental group occurrences; green: number of experimental group occurrences > number of control group occurrences; yellow: there is no significant difference between the two groups).